



ASCO Abstract Title	Primary Author	Link to ASCO Abstract No.
Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group Study.	I. L. Ray-Coquard	ASCO abstract no. 10032
Time to onset of progression after imatinib interruption and outcome of patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial.	A. Le Cesne	ASCO abstract no. 10033
Correlation of the topography of <i>KIT</i> exon 11 mutation with primary GIST location and predictive value for PFS in patients with advanced GIST: Results from the BFR14 randomized phase III trial of the French Sarcoma Group.	J. Blay	ASCO abstract no. 10019
Gastrointestinal stromal tumor (GIST) of the rectum and pararectal space: A French Sarcoma Group (FSG) retrospective review.	F. Duffaud	ASCO abstract no. 10055
Preliminary data of nilotinib in the first-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST).	P. G. Casali	ASCO abstract no. TPS332
Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3.	P. Reichardt	ASCO abstract no. 10017
Nonstandard dosing in gastrointestinal stromal tumors: A registry observation.	P. W. Pisters	ASCO abstract no. 10072
Adjuvant imatinib therapy of 208 gastrointestinal stromal tumor (GIST) patients: Dose, duration, and risk assessment.	J. C. Trent	ASCO abstract no. 10061
Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001.	C. L. Corless	ASCO abstract no. 10006
Validation of Joensuu risk criteria for primary resectable gastrointestinal stromal tumors.	P. Rutkowski	ASCO abstract no. 10018
Coexistence of gastrointestinal stromal tumor (GIST) with desmoid tumor (DT): Case series of 22 patients.	A. G. Dumont	ASCO abstract no. 10052
Succinate dehydrogenase in <i>KIT/PDGFR</i> A wild-type gastrointestinal stromal tumors.	K. A. Janeway	ASCO abstract no. 10008